Although sparsentan failed to reach statistical significance in the primary efficacy endpoint of reducing eGFR, its main clinical benefit is the meaningful reduction in proteinuria, an important marker for long-term renal outcomes in FSGS [ 1 , 4 ] .
← all excerpts
Bridging pathogenesis and therapy in focal segmental glomerulosclerosis: the rise of dual receptor blockade with sparsentan.
1
—
—